Goran Babic Selected Research

Infliximab (Remicade)

1/2019

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Goran Babic Research Topics

Disease

4	Rheumatoid Arthritis 01/2019 - 09/2008
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 10/2023
1	Atopic Dermatitis (Atopic Eczema) 12/2022
1	Inflammation (Inflammations) 12/2022
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2019
1	Rheumatic Diseases (Rheumatism) 01/2018
1	Disease Progression 09/2008
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2008

Drug/Important Bio-Agent (IBA)

2	Etanercept (Enbrel)FDA Link 01/2019 - 01/2018
2	GP2015IBA 01/2019 - 01/2018
2	Antirheumatic Agents (DMARD)IBA 01/2019 - 01/2018
2	Biosimilar PharmaceuticalsIBA 01/2019 - 01/2018
1	Interleukin-17 (Interleukin 17)IBA 12/2022
1	Infliximab (Remicade)FDA Link 01/2019
1	GP1111IBA 01/2019
1	Rituximab (Mabthera)FDA Link 09/2008

Therapy/Procedure

1	Curettage 10/2023
1	Therapeutics 09/2008